Recent performance context for CRISPR Therapeutics (CRSP)

CRISPR Therapeutics (CRSP) has drawn attention after a mixed stretch in its share performance, including a modest move over the past month and a decline in the past 3 months from recent levels.

At a latest share price of US$53.69, CRISPR Therapeutics has seen weaker momentum recently, with a 90 day share price return of 12.13% and a 1 year total shareholder return of 30.28%, while the 5 year total shareholder return of 67.36% underlines how sentiment around longer term risks and opportunities has shifted over time.

If this kind of price action has your attention, it could be a good moment to broaden your search across healthcare and biotech through healthcare stocks.

With the share price near US$53.69, a value score of 4, recent losses, and revenue still modest at US$38.337m against a net loss of US$488.297m, investors may question whether this reflects a genuine mispricing or whether expectations for future growth are already reflected in the current price.

Preferred Price-to-Book of 2.7x: Is it justified?

CRISPR Therapeutics shares last closed at $53.69, and on a P/B of 2.7x they sit in line with the wider US Biotechs industry and well below the selected peer group average.

The P/B ratio compares the market value of the company to its book value, which is essentially net assets on the balance sheet. For a business that is currently loss making, P/B can sometimes be a more practical yardstick than earnings-based ratios, because it focuses on what investors are paying for the underlying equity today rather than current profits.

Here, CRISPR Therapeutics trades at 2.7x book value, matching the broader US Biotechs industry average of 2.7x. In contrast, the peer average sits far higher at 13.6x. That gap suggests the market is assigning a lower premium to CRISPR Therapeutics equity than to many peers, even though our DCF work indicates the shares are trading 73.5% below an estimated future cash flow value of $202.67 based on the SWS DCF model.

Result: Price-to-book of 2.7x (UNDERVALUED)

However, you are still looking at a business with a US$488.297m net loss and a 5 year total shareholder return decline of 67.36%, which could challenge any undervaluation case.

Another angle on value: what if the cash flows are right?

The P/B of 2.7x puts CRISPR Therapeutics roughly in line with the US Biotechs average, but our DCF model estimates a cash flow value of $202.67 per share compared to the current $53.69. That difference presents a very different perspective, so which signal would you focus on more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 877 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own CRISPR Therapeutics Narrative

If you see the numbers differently or prefer to put your own spin on the data, you can build a full narrative in just a few minutes, starting with Do it your way.

A great starting point for your CRISPR Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If CRISPR Therapeutics has sparked your interest, do not stop here. Use the Simply Wall Street Screener to quickly explore other opportunities that match your style.

• Identify potential high risk, high reward opportunities by examining these 3519 penny stocks with strong financials that already show stronger financials than many expect at this price range.
• Explore the AI theme by scanning these 24 AI penny stocks that connect artificial intelligence applications to listed companies you can research in detail.
• Focus on value by checking these 877 undervalued stocks based on cash flows, which our models flag as priced below their estimated cash flow potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.